Paul Mischel

Q: What Schools Are Affiliated With Paul Mischel

Paul Mischel is affiliated with the following schools: University of Pennsylvania, Kobe University, Weill Cornell Medicine, University of California, San Diego, University of Verona, University of California, Los Angeles, Stanford University, University of North Carolina at Chapel Hill, University of California, San Francisco

Paul Mischel's AcademicInfluence.com Rankings

Paul Mischel

Biology

#6824

World Rank

#9626

Historical Rank

Molecular Biology

#1960

World Rank

#1991

Historical Rank

biology Degrees

Paul Mischel

Philosophy

#8940

World Rank

#12424

Historical Rank

Logic

#5948

World Rank

#7412

Historical Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Paul Mischel's Degrees

Masters Medicine University of California, San Francisco
PhD Molecular Biology University of California, San Francisco

Why Is Paul Mischel Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Paul S. Mischel is an American physician-scientist whose laboratory has made pioneering discoveries in the pathogenesis of human cancer. He is currently a Professor and Vice Chair of Research for the Department of Pathology and Institute Scholar of ChEM-H, Stanford University. Mischel was elected into the American Society for Clinical Investigation , serving as ASCI president in 2010/11. He was inducted into the Association of American Physicians, and was elected as a fellow of the American Association for the Advancement of Science.

(See a Problem?)

Paul Mischel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005) (1455)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (2007) (1225)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Gene Expression Profiling of Gliomas Strongly Predicts Survival (2004) (735)
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008) (568)
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. (2013) (513)
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment (2005) (484)
Cerebral Cortical Dysplasia Associated with Pediatric Epilepsy. Review of Neuropathologic Features and Proposal for a Grading System (1995) (466)
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. (2011) (455)
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. (2003) (449)
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. (2005) (441)
Metabolic state of glioma stem cells and nontumorigenic cells (2011) (421)
Glioblastoma: from molecular pathology to targeted treatment. (2014) (417)
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. (2011) (410)
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA (2014) (403)
Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity (2017) (399)
MR imaging correlates of survival in patients with high-grade gliomas. (2005) (386)
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target (2006) (357)
Single-cell analysis tools for drug discovery and development (2015) (352)
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain (2006) (345)
Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks (2006) (342)
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies (2010) (338)
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. (2013) (329)
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. (2011) (326)
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. (2009) (325)
Gene expression profiling identifies molecular subtypes of gliomas (2003) (312)
EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy (2009) (305)
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation (2013) (300)
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells (2011) (299)
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. (2012) (290)
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma (2015) (288)
Identification of molecular subtypes of glioblastoma by gene expression profiling (2003) (280)
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. (2008) (274)
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. (2011) (258)
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers (2009) (257)
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. (2006) (244)
When Is Hub Gene Selection Better than Standard Meta-Analysis? (2013) (244)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy (2006) (241)
Primary Glioblastomas Express Mesenchymal Stem-Like Properties (2006) (235)
Targeted Molecular Therapy of GBM (2003) (235)
Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma (2009) (234)
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 (2010) (234)
Bevacizumab and chemotherapy for recurrent glioblastoma (2009) (230)
Circular ecDNA promotes accessible chromatin and high oncogene expression (2019) (221)
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis (2009) (216)
DNA-microarray analysis of brain cancer: molecular classification for therapy (2004) (215)
Distinct transcription profiles of primary and secondary glioblastoma subgroups. (2006) (213)
Targeting SREBP-1-driven lipid metabolism to treat cancer. (2014) (207)
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age (2008) (206)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway (2011) (193)
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. (2016) (190)
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. (2008) (182)
Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. (2015) (177)
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. (2002) (174)
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) (2009) (172)
mTOR signaling in glioblastoma: lessons learned from bench to bedside (2010) (170)
Deregulation of a STAT3–Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and Invasiveness (2008) (166)
Probabilistic Radiographic Atlas of Glioblastoma Phenotypes (2013) (165)
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death (2012) (161)
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells (2008) (160)
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. (2015) (158)
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. (2009) (153)
Extrachromosomal oncogene amplification in tumour pathogenesis and evolution (2019) (151)
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers (2020) (149)
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (149)
Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. (2008) (148)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. (2012) (144)
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. (2013) (143)
Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy (2015) (138)
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets (2019) (136)
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors (2007) (136)
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors (2009) (135)
CD44v6 Regulates Growth of Brain Tumor Stem Cells Partially through the AKT-Mediated Pathway (2011) (132)
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. (2016) (132)
Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line (2004) (128)
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. (2013) (125)
Differential Induction of Glioblastoma Migration and Growth by Two Forms of Pleiotrophin* (2005) (123)
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. (2013) (120)
Genomic Landscape of Meningiomas (2009) (120)
Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies (2012) (119)
mTORC2 in the center of cancer metabolic reprogramming (2014) (119)
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling (2019) (114)
mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. (2017) (114)
Childhood generalized and mesial temporal epilepsies demonstrate different amounts and patterns of hippocampal neuron loss and mossy fibre synaptic reorganization. (1996) (113)
An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis (2009) (113)
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. (2013) (112)
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation (2010) (109)
Exploring the landscape of focal amplifications in cancer using AmpliconArchitect (2019) (108)
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 (2007) (107)
A Kinome-Wide RNAi Screen in Drosophila Glia Reveals That the RIO Kinases Mediate Cell Proliferation and Survival through TORC2-Akt Signaling in Glioblastoma (2013) (105)
PTEN dosage is essential for neurofibroma development and malignant transformation (2009) (105)
Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples (2008) (104)
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. (2013) (103)
Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. (2017) (102)
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240 (2012) (101)
Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides (2000) (101)
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. (2010) (99)
Anti-MHC Class I Antibody Activation of Proliferation and Survival Signaling in Murine Cardiac Allografts1 (2008) (98)
Targeted therapy for malignant glioma patients: Lessons learned and the road ahead (2009) (96)
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. (2011) (96)
Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. (2019) (96)
mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma (2012) (92)
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance (2015) (92)
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. (2013) (91)
Molecular classification of gliomas. (2016) (87)
Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone (2009) (86)
Glioma Stem Cell Specific Super Enhancer Promotes Polyunsaturated Fatty Acid Synthesis to Support EGFR Signaling. (2019) (86)
IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma (2019) (85)
Lymphomatosis cerebri Presenting as a Rapidly Progressive Dementia: Clinical, Neuroimaging and Pathologic Findings (1999) (85)
The Extracellular Domain of p75NTR Is Necessary to Inhibit Neurotrophin-3 Signaling through TrkA* (2001) (85)
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations (2011) (83)
RNA-Binding Protein Musashi1 Modulates Glioma Cell Growth through the Post-Transcriptional Regulation of Notch and PI3 Kinase/Akt Signaling Pathways (2012) (82)
Musashi1 Cooperates in Abnormal Cell Lineage Protein 28 (Lin28)-mediated Let-7 Family MicroRNA Biogenesis in Early Neural Differentiation*♦ (2011) (80)
PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. (2016) (79)
Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells (2019) (77)
A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma (2015) (76)
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition (2004) (75)
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas (2011) (75)
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. (2011) (75)
Coccidioidomycosis of the central nervous system: neuropathological and vasculopathic manifestations and clinical correlates. (1995) (71)
Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy (2003) (68)
Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab (2011) (66)
Bilateral neuropathologic changes in a child with hemimegalencephaly. (1997) (64)
Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma (2017) (62)
Hypoxia induces a phase transition within a kinase signaling network in cancer cells (2013) (62)
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients (2014) (58)
Hamartin and Tuberin Interaction With the G2/M Cyclin‐Dependent Kinase CDK1 and Its Regulatory Cyclins A and B (2001) (58)
Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. (2011) (58)
ecDNA hubs drive cooperative intermolecular oncogene expression (2020) (57)
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. (2012) (56)
Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence (2013) (56)
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies (2013) (56)
HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. (2006) (55)
Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients (2012) (54)
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. (2000) (54)
Breast cancer treatment and its effects on aging. (2019) (53)
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. (2009) (51)
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity (2017) (50)
Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling (2017) (50)
Pilot Study on “Pericytic Mimicry” and Potential Embryonic/Stem Cell Properties of Angiotropic Melanoma Cells Interacting with the Abluminal Vascular Surface (2013) (49)
Nerve growth factor signals via preexisting TrkA receptor oligomers. (2002) (49)
Hyperacute thermal lesions: MR imaging evaluation of development in the brain. (1995) (49)
Arteriovenous malformation animal model for radiosurgery: the rete mirabile. (1996) (48)
Extrachromosomal DNA - relieving heredity constraints, accelerating tumour evolution. (2020) (47)
On the role of 25-hydroxycholesterol synthesis by glioblastoma cell lines. Implications for chemotactic monocyte recruitment. (2013) (47)
The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas (2013) (46)
Significance of filamin A in mTORC2 function in glioblastoma (2015) (44)
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. (2015) (43)
Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi‐passageable neurosphere formation (2010) (42)
Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome (2005) (41)
ViFi: accurate detection of viral integration and mRNA fusion reveals indiscriminate and unregulated transcription in proximal genomic regions in cervical cancer (2018) (39)
Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism (2011) (39)
Cortical Dysplasia, Genetic Abnormalities and Neurocutaneous Syndromes (1999) (39)
Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance (2014) (38)
Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit. (2008) (38)
Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (38)
Challenges in identifying cancer genes by analysis of exome sequencing data (2016) (38)
Sneddon's Syndrome Is a Thrombotic Vasculopathy (1995) (37)
Charting the course across the blood-brain barrier. (2011) (36)
Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. (1996) (35)
AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models (2015) (35)
Suppression of G-protein–Coupled Receptor Kinase 3 Expression Is a Feature of Classical GBM That Is Required for Maximal Growth (2011) (34)
Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA (2022) (34)
Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. (2005) (34)
Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells (2020) (33)
Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas (2014) (32)
mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression (2018) (31)
A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients (2005) (31)
Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma* (2014) (31)
Cancer metabolism as a central driving force of glioma pathogenesis (2016) (30)
Molecular and Genetic Determinants of Glioma Cell Invasion (2017) (29)
New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target? (2011) (29)
Will kinase inhibitors make it as glioblastoma drugs? (2012) (29)
New Roles for Galectins in Brain Tumors—From Prognostic Markers to Therapeutic Targets (2005) (29)
Lymphomatosis Cerebri Presenting as Rapidly Progressive Dementia (2007) (28)
AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas (2010) (28)
Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. (2015) (27)
Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways (2014) (27)
An LXR agonist promotes GBM cell death through inhibition of an EGFR / AKT / SREBP-1 / LDLR-dependent pathway (2011) (27)
AmpliconReconstructor integrates NGS and optical mapping to resolve the complex structures of focal amplifications (2020) (27)
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. (2004) (25)
Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context. (2018) (25)
mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment (2015) (25)
Metabolic reprogramming in the pathogenesis of glioma: Update (2019) (24)
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug (2021) (24)
Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage (2013) (23)
mTOR complex 2 is an integrator of cancer metabolism and epigenetics. (2020) (23)
Extrachromosomal DNA: An Emerging Hallmark in Human Cancer. (2021) (22)
Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression (2021) (22)
EcSeg: Semantic Segmentation of Metaphase Images Containing Extrachromosomal DNA (2019) (20)
Striking the balance between PTEN and PDK1: it all depends on the cell context. (2009) (20)
Extrachromosomal DNA (ecDNA) in cancer pathogenesis. (2021) (19)
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response (2018) (18)
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations (2019) (18)
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors. (2013) (18)
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer (2019) (17)
Using molecular information to guide brain tumor therapy (2006) (17)
mTORC2 dictates Warburg effect and drug resistance (2014) (17)
Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study. (2013) (16)
mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma (2019) (16)
Lost - and found - in translation. (2011) (16)
Targeting epidermal growth factor receptor co‐dependent signaling pathways in glioblastoma (2018) (15)
Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. (2012) (15)
Extrachromosomal DNA in HPV-Mediated Oropharyngeal Cancer Drives Diverse Oncogene Transcription (2021) (14)
mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling (2016) (14)
Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM (2020) (14)
Protein Acetylation at the Interface of Genetics, Epigenetics and Environment in Cancer (2021) (13)
The evolutionary dynamics of extrachromosomal DNA in human cancers (2022) (13)
HOT models in flux: mitochondrial glucose oxidation fuels glioblastoma growth. (2012) (12)
Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma (2016) (12)
Principles of ecDNA random inheritance drive rapid genome change and therapy resistance in human cancers (2021) (12)
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) (2008) (11)
Fast Metabolic Response to Drug Intervention Through Analysis on a Miniaturized, Highly Integrated Molecular Imaging System (2013) (11)
Erratum: Genomic Landscape of Meningiomas (Brain Pathology (2010) 20 (751-762)) (2011) (11)
Determining PTEN Functional Status by Network Component Deduced Transcription Factor Activities (2012) (11)
Multiple functions of a glioblastoma fusion oncogene. (2013) (10)
Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH (2021) (10)
Title Combination therapy with vemurafenib ( PLX 4032 / RG 7204 ) and metformin in melanoma cell lines with distinct driver mutations (2011) (10)
Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases* (2012) (9)
Creutzfeldt-Jakob disease with mixed transcortical aphasia: insights into echolalia. (1994) (8)
Single cell analytic tools for drug discovery and development (2016) (8)
Gene expression profiling identifies molecular subtypes of gliomas (2006) (8)
Correction: RNA-Binding Protein Musashi1 Modulates Glioma Cell Growth through the Post-Transcriptional Regulation of Notch and PI3 Kinase/Akt Signaling Pathways (2012) (7)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
Neuropathology and Molecular Pathogenesis of Primary Brain Tumors (2001) (6)
Cancer Therapy : Preclinical The mTOR Kinase Inhibitors , CC 2141 and CC 2142 , Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas (2013) (6)
Frequent extrachromosomal oncogene amplification drives aggressive tumors (2019) (6)
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies (2013) (6)
Acyl-CoA-Binding Protein Fuels Gliomagenesis. (2019) (6)
Research report Robustness of gene expression profiling in glioma specimen samplings and derived cell lines (2005) (5)
BAP1 methylation: a prognostic marker of uveal melanoma metastasis (2021) (5)
Emerging function of mTORC 2 as a core regulator in glioblastoma : metabolic reprogramming and drug resistance (2015) (5)
Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. (2014) (5)
Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab (2010) (5)
The landscape of extrachromosomal circular DNA in medulloblastoma (2021) (5)
Same Script, Different Cast: Different Cell Origins Shape Molecular Features and Therapeutic Response in Glioblastoma. (2020) (4)
The metabolomic landscape plays a critical role in glioma oncogenesis (2022) (4)
Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. (2011) (4)
Gene regulation on extrachromosomal DNA (2022) (4)
Tumor suppressive miR-148 a is silenced by CpG island hypermethylation in IDH 1 mutant gliomas (2014) (4)
Alien hand syndrome in adult onset orthochromatic leukodystrophy: Disconnection of a limb from supplementary motor areas (1996) (4)
Metabolic Reprogramming in Brain Cancer: A Coordinated Effort (2015) (3)
Glioblastomas derived from genetically modified pluripotent stem cells recapitulate pathobiology (2019) (3)
NT-39GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES (2014) (3)
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges (2022) (2)
Extrachromosomal DNA (ecDNA) carrying amplified oncogenes as a biomarker for insensitivity to pembrolizumab treatment in gastric cancer patients. (2020) (2)
CELL BIOLOGY AND SIGNALING (2010) (2)
LOSS OF HETEROZYGOSITY IN SPORADIC CORTICAL. DYSPLASIA FOR DNA MARKERS IN THE REGION OF THE TUBEROUS SCLEROSIS (TSC1) GENE ON CHROMOSOME 9q34: 11 (1995) (2)
HDJ-2 is an important target of farnesyltransferase inhibitor, R115777, induced radiosensitization (2005) (2)
Noninvasive Imaging of A V B 3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib (2009) (2)
Epigenetic dysregulation from chromosomal transit in micronuclei (2022) (2)
Comprehensive analysis of clustered mutations in cancer reveals recurrent APOBEC3 mutagenesis of ecDNA (2021) (2)
Reconstructing and characterizing focal amplifications in cancer using AmpliconArchitect (2018) (2)
Circular ecDNA promotes accessible chromatin and high oncogene expression (2019) (2)
Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. (2012) (2)
Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation (2022) (2)
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients (Journal of Clinical Investigation (2012) 122, 1, (253-266) DOI: 10.1172/JCI59334) (2012) (2)
Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus (2022) (2)
DESTRUCTIVE LESIONS ASSOCIATED WITH CORTICAL DYSPLASIA: ANALYSIS OF 11 CASES (1995) (1)
Discovery and Functional Characterization of Pro-growth Enhancers in Human Cancer Cells (2021) (1)
An Update on Correlative Molecular Endpoints from RTOG 0211: Phase I/II Study of Gefitinib + Radiation for Newly Diagnosed Glioblastoma Patients (2008) (1)
Omics and Prognostic Markers (2010) (1)
Extrachromosomal DNA (ecDNA): an origin of tumor heterogeneity, genomic remodeling, and drug resistance (2022) (1)
Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers (2020) (1)
Abstract 1220: ErbB4: A novel therapeutic target in glioblastoma multiforme (2012) (1)
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients (2014) (1)
Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma. (2017) (1)
Fyn and Src are Effectors of Oncogenic EGFR Signaling in Glioblastoma Patients (2009) (1)
Central Nervous System (1974) (1)
Autocrine endothelin-3 / endothelin receptor B signaling maintains cellular and molecular properties of tumorigenic glioblastoma stem cells (2011) (1)
A case for a science-informed perspective on health care reform. (2009) (1)
AmpliconReconstructor: Integrated analysis of NGS and optical mapping resolves the complex structures of focal amplifications in cancer (2020) (1)
GBM Mutants in EGFR Identifies Convergent Evolution of Independent Greater Than the Sum of Its Parts : Single-Nucleus Sequencing (2014) (1)
Extrachromosomal DNA in Cancer. (2022) (1)
LYMPHOID HYPOPHYSITIS: AN UNCOMMON INFLAMMATORY PSEUDOTUMOR (1995) (0)
Significance of filamin A in mTORC2 function in glioblastoma (2015) (0)
cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. (2011) (0)
Abstract SY26-02: Targeting lipogenesis in EGFR-activated glioblastomas (2011) (0)
Author Correction: Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells (2020) (0)
Correction: PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. (2022) (0)
Exploring the landscape of focal amplifications in cancer using AmpliconArchitect (2019) (0)
Science Signaling Podcast: 15 December 2009 (2009) (0)
GEN-14 Dual regulation of histone methylation by mTOR complexes drives the progression of EGFR-mutant glioblastoma (2020) (0)
ISOLATED CORTICAL DYSPLASIA SHOWS LOSS OF HETEROZYGOSITY IN THE REGION OF THE TUBEROUS SCLEROSIS-1 GENE (1995) (0)
Presentation Title: Neural stem cells, brain tumors, and brain tumor stem cells (2008) (0)
CBM-17INCREASING EXPRESSION OF GLUTAMINASE C (GAC) mRNA IN MALIGNANT GLIOMAS (2015) (0)
STEM-20. A CANCER STEM CELL-SELECTIVE APOPTOSIS-INDUCING SMALL MOLECULE FOR THE TREATMENT OF GBM (2020) (0)
Methods and materials for examining vias associated with the progression of glioblastoma. (2003) (0)
Abstract 3768: Epigenetic dysregulation from chromosomal transit in micronuclei (2022) (0)
315 Molecular signature of the PTEN tumor suppressor-identification of IGFBP2 as a surrogate marker for PTEN/Akt signaling (2004) (0)
A Network-Based Gene Screening Approach For Improving the Validation Success of Microarrays (2006) (0)
Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells (2020) (0)
Stimulation of neural stem cell self-renewal via NADPH oxidase-generated ROS and inactivation of the tumor suppressor PTEN (2007) (0)
American Association for Cancer Research Genetics and Biology (2010) (0)
CBIO-12. GTP METABOLIC SWITCH LEADS TO NUCLEOLAR TRANSFORMATION AND MALIGNANT GROWTH OF GLIOBLASTOMA (2017) (0)
IN THE SPOTLIGHT Greater Than the Sum of Its Parts: Single-Nucleus Sequencing Identifi es Convergent Evolution of Independent EGFR Mutants in GBM (2014) (0)
AMPK suppressed glioma growth by inhibiting lipogenesis, and by synergistically inhibiting mTOR activity with PTEN (2007) (0)
Regulates Acid Metabolism in Cancer by of the Cystine-Glutamate Antiporter xCT. (2017) (0)
DDEL-04AshwaMAX AND WITHAFERIN A INHIBITS GLIOMAS IN CELLULAR AND MURINE ORTHOTOPIC MODELS (2015) (0)
Abstract 1923: The mTOR kinase inhibitor, CC214, preferentially blocks the growth of EGFRvIII-activated glioblastomas (2012) (0)
FSMP-08. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS (2021) (0)
Form follows function in cancer genomes (2022) (0)
World Health Organization SSM : superficial spreading melanoma LMM : lentigo maligna melanoma NM : nodular melanoma ALM : acral lentiginous melanoma CLASSIFICATION OF MELANOCYTIC NEOPLASMS (2014) (0)
Vicious Circles – how changes in the shape of DNA can drive cancer (2020) (0)
Abstract 5607: TLE4 is a key modulator of resistance to mTOR pathway specific inhibition in glioblastoma (2012) (0)
STEM-22. TARGETING PYRIMIDINE SYNTHESIS ACCENTUATES MOLECULAR THERAPY RESPONSE IN GLIOBLASTOMA STEM CELLS (2019) (0)
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets (2019) (0)
Changes in tumor invasiveness in response to src-kinase inhibition monitored by PET with radiolabeled RGD-peptides (2008) (0)
Abstract 3130: Extrachromosomal DNA in the cancerous transformation of Barrett’s esophagus (2023) (0)
Thomas and Autophagy in Hepatocellular Carcinoma mTOR Inhibitors Synergize on Regression , Reversal of Gene Expression (2012) (0)
Genomic and Molecular Neuro-Oncology (2004) (0)
Shared Intelligence: A Patient-Derived, Deeply Characterized Glioblastoma Cell Line Resource (2015) (0)
Molecular Targeting of Brain Tumors (2017) (0)
Data S1. Evaluation of Fluoxetine in Overall Survival of GBM Patients Using Electronic Medical Records from The IBM MarketScan Dataset (2021) (0)
TMOD-42. CRISPR/Cas9-EDITED HUMAN NEURAL STEM CELLS GIVE RISE TO BRAIN TUMORS RESEMBLING GLIOBLASTOMAS (2017) (0)
De novo GTP pathway is required for the proliferation of glioblastoma (2016) (0)
TMOD-28. AUTHENTIC HUMAN GLIOMA MODELING USING GENETICALLY ENGINEERED INDUCED PLURIPOTENT STEM CELLS (2019) (0)
66 Proffered Paper: PTEN Phosphorylation by Fibroblast Growth Factor Receptors and SRC Mediates Resistance to Epidermal Growth Factor Receptor Inhibitors in Glioblastoma (2012) (0)
Combined analysis of O 6 -methylguani ne-DNA methyltransferase protein expression and promoter methyl ation provides opti mized prognosticati on of gli oblastoma outcome NEURO- ONCOLOGY (2015) (0)
Protect Cancer Cells from Lipotoxicity An Essential Requirement for the SCAP / SREBP Signaling Axis to (2013) (0)
Cellular and Molecular Properties of Glioblastoma Stem Cells Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains (2011) (0)
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling (2019) (0)
Extrachromosomal oncogene amplification in tumour pathogenesis and evolution (2019) (0)
Cancer avatars derived from genetically engineered pluripotent stem cells allow for longitudinal assessment of tumor development (2019) (0)
Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. (2011) (0)
Murine Cardiac Allografts Proliferation and Survival Signaling in Anti-MHC Class I Antibody Activation of (2008) (0)
Transcriptional immune suppression and upregulation of double stranded DNA damage and repair repertoires in ecDNA-containing tumors (2023) (0)
Abstract SY03-02: Extrachromosomal DNA (ecDNA): Cancer's dynamic circular genome (2022) (0)
1657PHYPOXIA REGULATION OF SENSITIVITY TO THE MECHANISTIC TARGET OF RAPAMYCIN KINASE INHIBITION (MTORKI) IN GLIOBLASTOMA MULTIFORME. (2014) (0)
Title Stem cell associated gene expression in glioblastoma multiforme : relationship to survival and the subventricular zone Permalink (2010) (0)
DIFFUSE CEREBRAL ANGIOMATOSIS AS A CAUSE OF PEDIATRIC EPILEPSY (1996) (0)
A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death. (2023) (0)
Abstract 4321: EGFR signaling in glioblastoma regulates the expression of a brain specific isoform ofalphaPIX/Arhgef6to promote invasion (2012) (0)
cell context Striking the balance between PTEN and PDK1: it all depends on the (2009) (0)
GRK expression in GBM (2011) (0)
Abstract PR09: Single cell phosphoproteomics identifies adaptive network dynamics of mTOR inhibitor resistance and defines effective combination therapy in glioblastoma (2015) (0)
Abstract IA11: Targeting PI3K-mTOR signaling in glioblastoma: A central role for mTORC2 in drug resistance and metabolic reprogramming (2015) (0)
The prevalence of favorable PTEN and MGMT biomarker status in 66 glioblastomas (2008) (0)
Author Correction: Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cells (2020) (0)
Correction: RNA-Binding Protein Musashi1 Modulates Glioma Cell Growth through the Post-Transcriptional Regulation of Notch and PI3 Kinase/Akt Signaling Pathways (2013) (0)
Cancer Genes and Genomics Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (0)
Abstract 95: The landscape of extrachromosomal circular DNA in medulloblastoma subgroups (2021) (0)

This paper list is powered by the following services:

Other Resources About Paul Mischel

en.wikipedia.org

What Schools Are Affiliated With Paul Mischel?

Paul Mischel is affiliated with the following schools:

Paul Mischel's Academic­Influence.com Rankings

Paul Mischel's Degrees

Why Is Paul Mischel Influential?

Paul Mischel's Published Works

Published Works

Other Resources About Paul Mischel

What Schools Are Affiliated With Paul Mischel?

Paul Mischel's AcademicInfluence.com Rankings